Virtual Seminar: Control of TGF-beta Signaling and Epithelial-Mesenchymal Transition
Pioneers in Biomedical Research Seminar presented by the Fralin Biomedical Research Institute at VTC
Epithelial-mesenchymal transition (EMT) is a normal differentiation process during development that enables epithelial cells to partially or completely repress epithelial junctions and reprogram gene expression, resulting in more motile and often more invasive cell behavior. EMT, which is generally thought of as a reversible process, allows the cells to reach new destinations and generate new cell populations. EMT is also repurposed pathologically during fibrosis and cancer progression, and allows carcinoma cells to disseminate, while additionally enabling the cells to acquire stem cell characteristics and cancer drug resistance. Studying the activities and signaling pathways of a secreted growth factor and cytokine, named transforming growth factor-beta (TGF-beta), it was shown a long time ago that TGF-beta can induce EMT. Consistent with this notion and its known activities, increased TGF-beta signaling is now seen as a driver of fibrosis and cancer dissemination that leads to metastasis. Dr. Dernyck's research highlights the cooperation of two signaling pathways, Smad signaling and Akt-mTOR signaling, in the progression and completion of EMT, and illustrates that prolonged exposure of cancer cells stabilizes EMT, which stands in contrast to the general notion that EMT is always reversible. When compared to reversible EMT, stabilized EMT has increased stem cell properties and cancer stem cell properties that depend on mTOR signaling. The recognition of the roles of EMT in fibrosis and cancer, and the key role of TGF-beta as driver of the EMT process allow for therapeutic opportunities.
This is a free event hosted by the Fralin Biomedical Research Institute and co-sponsored by the institute's Cancer Research Group. The Pioneers in Biomedical Research Seminar Series, which runs annually from September to May, has featured leading biomedical researchers from throughout the country since the program began in 2012. Presented virtually via Zoom primarily for research and clinical audiences, the lectures are also open to all members of the Virginia Tech community including graduate students, undergraduates, faculty, and staff, as well as the public.
You May Also Be Interested In...
General ItemVirtual Seminar: Reprogramming the Brain Cancer Stem Cell
March 5, 2021, 11 a.m. | John Laterra, M.D., Ph.D. | Pioneers in Biomedical Research Seminar Series
General ItemVirtual Seminar: Effect of Contemporary Societal Exposures on Adolescent Behavioral Health
March 12, 2021, 11 a.m. | Adam Matthew Leventhal, Ph.D. | Pioneers in Biomedical Research Seminar Series
General ItemVirtual Public Lecture: Genes Regulating Sleep and Circadian Rhythms
March 25, 2021, 5:30 p.m. | Michael Young, Ph.D. | Maury Strauss Distinguished Public Lecture **Awarded the 2017 Nobel Prize in Physiology or Medicine**
General ItemVirtual Seminar: The Epigenetic Basis of Memory Formation and Dysregulation in Memory Disorders
April 2, 2021, 11 a.m. | Farah Lubin, Ph.D. | Pioneers in Biomedical Research Seminar Series
General ItemVirtual Lecture: Title to be announced
April 2, 2021, 1 p.m. | Alain Dagher, M.D. | Timothy A. Johnson Medical Scholar Seminar Series
Rik Derynck, Ph.D.
Professor, Department of Cell/Tissue Biology, and Department of Anatomy; Co-Director, UCSF Institute of Regeneration Medicine; Co-Director, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco